Anus Benign Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Anus Benign Neoplasm

MalaCards integrated aliases for Anus Benign Neoplasm:

Name: Anus Benign Neoplasm 12 15
Anal Neoplasm 12 17
Neoplasm of Anus 12
Anus Neoplasms 44
Anal Tumors 12


External Ids:

Disease Ontology 12 DOID:4551
MeSH 44 D001005
NCIt 50 C2877
UMLS 72 C0003463

Summaries for Anus Benign Neoplasm

MalaCards based summary : Anus Benign Neoplasm, also known as anal neoplasm, is related to anal canal squamous cell carcinoma and anal canal carcinoma. An important gene associated with Anus Benign Neoplasm is CEP170 (Centrosomal Protein 170), and among its related pathways/superpathways is MAP Kinase Signaling. The drugs Octreotide and Imiquimod have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and cervix, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Related Diseases for Anus Benign Neoplasm

Diseases related to Anus Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 101)
# Related Disease Score Top Affiliating Genes
1 anal canal squamous cell carcinoma 30.9 SERPINB3 KRT5 CDKN2A
2 anal canal carcinoma 30.7 KRT7 CDKN2A
3 anal canal adenocarcinoma 30.7 KRT7 CDX2
4 papilloma 30.0 KRT7 KRT5 CDKN2A
5 anus cancer 28.6 SETD1A SERPINB3 RORC KRT7 KRT5 CDX2
6 anus sarcoma 11.2
7 histiocytic sarcoma 10.7 CDKN2A BRAF
8 bladder squamous cell carcinoma 10.6 CDKN2A BRAF
9 spitz nevus 10.6 CDKN2A BRAF
10 acral lentiginous melanoma 10.6 CDKN2A BRAF
11 optic nerve sheath meningioma 10.6 KRT5 CDKN2A
12 keratinizing squamous cell carcinoma 10.6 KRT5 CDKN2A
13 vulva squamous cell carcinoma 10.5 SERPINB3 CDKN2A
14 lymphoepithelioma-like thymic carcinoma 10.5 KRT5 CDKN2A
15 papillary craniopharyngioma 10.4 KRT7 BRAF
16 ovary neuroendocrine neoplasm 10.4 KRT7 CDX2
17 appendix adenocarcinoma 10.4 KRT7 CDX2
18 anus adenocarcinoma 10.4 KRT7 CDX2
19 mucinous adenofibroma 10.4 KRT7 CDX2
20 glandular cystitis 10.4 KRT7 CDX2
21 bladder carcinoma in situ 10.4 KRT7 CDKN2A
22 ceruminoma 10.4 KRT7 KRT5
23 benign breast adenomyoepithelioma 10.4 KRT7 KRT5
24 breast adenomyoepithelioma 10.4 KRT7 KRT5
25 endocervical carcinoma 10.4 KRT7 CDKN2A
26 balloon cell malignant melanoma 10.4 KRT7 KRT5
27 bile duct adenoma 10.4 KRT7 CDKN2A
28 malignant spiradenoma 10.4 KRT7 KRT5
29 adenoid basal cell carcinoma 10.4 KRT7 CDKN2A
30 vulval paget's disease 10.4 KRT7 CDKN2A
31 benign mesothelioma 10.4 KRT7 KRT5
32 epithelial predominant wilms' tumor 10.4 KRT7 CDX2
33 middle ear adenoma 10.4 KRT7 KRT5
34 bile duct mucoepidermoid carcinoma 10.4 KRT7 KRT5
35 duodenum adenocarcinoma 10.4 KRT7 CDX2
36 sensory organ benign neoplasm 10.4 KRT7 KRT5
37 large cell acanthoma 10.4 KRT7 KRT5
38 renal pelvis adenocarcinoma 10.4 KRT7 HCK
39 apocrine sweat gland neoplasm 10.4 KRT7 KRT5
40 gastric diffuse adenocarcinoma 10.3 KRT7 CDX2
41 metanephric adenoma 10.3 KRT7 BRAF
42 appendix disease 10.3 KRT7 CDX2
43 thymus adenocarcinoma 10.3 KRT7 CDX2
44 ovarian mucinous adenocarcinoma 10.3 KRT7 CDX2
45 pylorospasm 10.3 HCK GAST
46 glycogen-rich clear cell breast carcinoma 10.3 KRT7 CDKN2A
47 jejunal adenocarcinoma 10.3 KRT7 CDX2
48 bladder adenocarcinoma 10.3 KRT7 CDX2
49 chronic cystitis 10.3 KRT7 CDX2
50 vulvar disease 10.3 SERPINB3 KRT7 CDKN2A

Graphical network of the top 20 diseases related to Anus Benign Neoplasm:

Diseases related to Anus Benign Neoplasm

Symptoms & Phenotypes for Anus Benign Neoplasm

MGI Mouse Phenotypes related to Anus Benign Neoplasm:

# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.7 BRAF CD4 CDKN2A CDX2 GAST KRT5
2 homeostasis/metabolism MP:0005376 9.7 BRAF CD4 CDKN2A CDX2 GAST HCK
3 mortality/aging MP:0010768 9.36 BRAF CD4 CDKN2A CDX2 GAST HCK

Drugs & Therapeutics for Anus Benign Neoplasm

Drugs for Anus Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
5 Antineoplastic Agents, Hormonal Phase 3
6 interferons Phase 3
7 Adjuvants, Immunologic Phase 3
8 Anesthetics Phase 3
9 Interferon Inducers Phase 3
10 Alkylating Agents Phase 2, Phase 3
11 Mitomycins Phase 2, Phase 3
12 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
13 Anti-Bacterial Agents Phase 2, Phase 3
14 Antibiotics, Antitubercular Phase 2, Phase 3
15 Immunologic Factors Phase 2, Phase 3
16 Immunosuppressive Agents Phase 2, Phase 3
17 Antimetabolites Phase 2, Phase 3
18 Antimetabolites, Antineoplastic Phase 2, Phase 3
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
Cidofovir Approved Phase 2 113852-37-2 60613
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
Aldesleukin Approved Phase 1, Phase 2 85898-30-2, 110942-02-4
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
Bevacizumab Approved, Investigational Phase 2 216974-75-3
nivolumab Approved Phase 2 946414-94-4
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
Ipilimumab Approved Phase 2 477202-00-9
Durvalumab Approved, Investigational Phase 2 1428935-60-7
Pomalidomide Approved Phase 2 19171-19-8
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
Panitumumab Approved, Investigational Phase 1, Phase 2 339177-26-3 50070211
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
Palonosetron Approved, Investigational Phase 2 119904-90-4, 135729-61-2, 135729-56-5 148211
Alovudine Investigational Phase 2 25526-93-6
38 Antineoplastic Agents, Phytogenic Phase 2
39 Tubulin Modulators Phase 2
40 Albumin-Bound Paclitaxel Phase 2
41 Antimitotic Agents Phase 2
42 Antiviral Agents Phase 2
43 Dideoxynucleosides Phase 2
44 Reverse Transcriptase Inhibitors Phase 2
45 Anti-Retroviral Agents Phase 2
46 Protein Kinase Inhibitors Phase 2
47 ON 01910 Phase 2
48 Anti-HIV Agents Phase 1, Phase 2
49 Analgesics Phase 2
50 Analgesics, Non-Narcotic Phase 2

Interventional clinical trials:

(show top 50) (show all 152)
# Name Status NCT ID Phase Drugs
1 Intensification Therapy for Locally Advanced Epidermoid Cancer of the Anal Canal - Phase III Intergroup Study Unknown status NCT00003652 Phase 3 cisplatin;fluorouracil
2 A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women Completed NCT01651949 Phase 3
3 A Randomized Clinical Trial of Infrared Coagulator (IRC) Ablation Versus Expectant Management of Intra-Anal High Grade Intraepithelial Neoplasia (HGAIN) in HIV-infected Adults Completed NCT01164722 Phase 3
4 A Randomized, Double Blind, Placebo-Controlled Phase III Study To Determine The Efficacy Of Sandostatin LAR® Depot (Octreotide Acetate) In Preventing Or Reducing The Severity Of Chemoradiation-Induced Diarrhea In Patients With Anal Or Rectal Cancer Completed NCT00075868 Phase 3 octreotide acetate
5 A Phase III Randomized Study of 5-Fluorouracil, Mitomycin-C, and Radiotherapy Versus 5-Fluorouracil, Cisplatin, and Radiotherapy in Carcinoma of the Anal Canal Completed NCT00003596 Phase 3 cisplatin;fluorouracil;mitomycin C
6 Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy Recruiting NCT02369939 Phase 3 Mitomycin C;5-Fluorouracil
7 ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study Recruiting NCT02135419 Phase 3 imiquimod;fluorouracil
8 Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer Enrolling by invitation NCT02526953 Phase 3 Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
9 Continuous Fluorouracil Plus Mitomycin C Versus Mitomycin C Plus Cisplatin As Chemotherapy Combination In Combined Radiochemotherapy For Locally Advanced Anal Cancer. A Phase II-III Study Terminated NCT00068744 Phase 2, Phase 3 cisplatin;fluorouracil;mitomycin C
10 Phase II Nonrandomized Multicenter Study of the Impact of Radiochemotherapy (65 Gy + Cisplatin + 5FU) Combined With Cetuximab in Patients Presenting With Locally Advanced Anal Cancer Unknown status NCT00955240 Phase 2 cisplatin;fluorouracil
11 An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease Unknown status NCT02051868 Phase 2 Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
12 Phase II Study for Treatment of Anal HSIL Through Use of a Chinese Herbal Topical Cream Completed NCT00622440 Phase 2 AIJP (Arnebia Indigo Jade Pearl);Placebo
13 A Phase I/II Trial of SGN-00101 in the Treatment of High-Grade Anal Intraepithelial Neoplasia (AIN) in HIV-Positive Individuals Completed NCT00052897 Phase 1, Phase 2
14 A Phase II, Prospective, Open-label, Pilot Study of the Tolerability, Safety, and Efficacy of Argon Plasma Coagulation for the Treatment of Anal Intraepithelial Neoplasia Grade 2 or 3 in HIV-positive Men Having Sex With Men Completed NCT00428285 Phase 2
15 A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal. Completed NCT01941966 Phase 2 Capecitabine;Mitomycins
16 Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging Completed NCT01717391 Phase 2 fluorothymidine F 18
17 AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males Completed NCT01209325 Phase 2
18 A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
19 A Phase II Study of Capecitabine (Xeloda)/Oxaliplatin (Eloxatin) With Concomitant Radiotherapy (XRT), XELOX/RT in Squamous Cell Carcinoma of the Anal Canal Completed NCT00093379 Phase 2 Capecitabine;Oxaliplatin
20 Phase II Trial of Combined Modality Therapy Plus Cetuximab in HIV-Associated Anal Carcinoma Completed NCT00324415 Phase 2 cisplatin;fluorouracil
21 Phase IIA Trial of 1% Topical Cidofovir for Treatment of High-Grade Perianal Squamous Intraepithelial Lesions in HIV-Infected Men and Women Completed NCT00550589 Phase 2 cidofovir
22 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
23 A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal Completed NCT00423293 Phase 2 fluorouracil;mitomycin C
24 Phase 2 Trial to Assess the Efficacy and Safety of Chemoradiation With 5-fluorouracil, Mytomicin C and Panitumumab as a Treatment for Anal Squamous Cell Carcinoma Completed NCT01285778 Phase 2 panitumumab, mytomicin C, 5-FU, radiation
25 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
26 A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2 Recruiting NCT03499795 Phase 2
27 A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer Recruiting NCT03018418 Phase 2 Chemotherapy
28 Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer Recruiting NCT03381352 Phase 2 Capecitabine;Mitomycin C
29 A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer Recruiting NCT03233711 Phase 2
30 A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients Recruiting NCT02865135 Phase 1, Phase 2 DPX-E7 vaccine
31 A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors Recruiting NCT03074513 Phase 2 Atezolizumab
32 A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Refractory Metastatic Anal Cancer Recruiting NCT02919969 Phase 2 Pembrolizumab
33 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand Recruiting NCT03302858 Phase 2
34 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
35 Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life Recruiting NCT02701088 Phase 2 5Fluorouracile and Mitomycin-C
36 A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Recruiting NCT03519295 Phase 2 MPDL3280A;mDCF
37 Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: A Feasibility Trial Recruiting NCT03690921 Phase 2 Cisplatin;Fluorouracil
38 A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons Recruiting NCT02437851 Phase 2
39 A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal Recruiting NCT02314169 Phase 2
40 A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers Recruiting NCT03439085 Phase 2
41 A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT) Recruiting NCT03870607 Phase 2
42 M7824 in Subjects With HPV Associated Malignancies Recruiting NCT03427411 Phase 2 M7824
44 Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions Active, not recruiting NCT03113942 Phase 2 Pomalidomide 2 MG Oral Capsule [Pomalyst]
45 Phase I-II on Radiochemotherapy Combined With Panitumumab in the Treatment of Localised Epidermoid Carcinoma of the Anus Active, not recruiting NCT01581840 Phase 1, Phase 2 radiochemotherapy;Panitumumab
46 Randomized Phase 2 Trial of Cetuximab and Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment Active, not recruiting NCT03944252 Phase 2 Avelumab;Cetuximab
47 InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease Active, not recruiting NCT02560298 Phase 2 Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
48 Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma. Active, not recruiting NCT02402842 Phase 2 Docetaxel, Cisplatin and 5-Fluorouracil
49 Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma Active, not recruiting NCT00316888 Phase 2 cisplatin;fluorouracil
50 A Phase II Study Designed to Evaluate the Value of Alkagin Paste in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy Terminated NCT01408407 Phase 2

Search NIH Clinical Center for Anus Benign Neoplasm

Cochrane evidence based reviews: anus neoplasms

Genetic Tests for Anus Benign Neoplasm

Anatomical Context for Anus Benign Neoplasm

MalaCards organs/tissues related to Anus Benign Neoplasm:

Testes, Lung, Cervix, Lymph Node, Liver, Pancreas, Breast

Publications for Anus Benign Neoplasm

Articles related to Anus Benign Neoplasm:

# Title Authors PMID Year
A rare case of perianal granular cell tumor: case report and literature review. 38
28603602 2017
Pathology of Anal Cancer. 38
27889037 2017
Loss of histone variant macroH2A2 expression associates with progression of anal neoplasm. 38
26658220 2016
[Screening of intraepithelial anal neoplasm]. 38
24210980 2014
[Anal endosonography in the diagnosis of anal neoplasm]. 38
12557448 2002
[Anal neoplasm. Considerations on 100 cases]. 38
5614746 1967

Variations for Anus Benign Neoplasm

Expression for Anus Benign Neoplasm

Search GEO for disease gene expression data for Anus Benign Neoplasm.

Pathways for Anus Benign Neoplasm

Pathways related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.85 PEBP1 HCK BRAF

GO Terms for Anus Benign Neoplasm

Biological processes related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of peptidase activity GO:0010466 9.43 SPINK5 SERPINB3 PEBP1
2 cornification GO:0070268 9.33 SPINK5 KRT7 KRT5
3 negative regulation of proteolysis GO:0045861 9.32 SPINK5 SERPINB3
4 regulation of T cell differentiation GO:0045580 8.96 SPINK5 BRAF
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 8.8 INSRR HCK CD4

Molecular functions related to Anus Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase inhibitor activity GO:0030414 9.13 SPINK5 SERPINB3 PEBP1
2 serine-type endopeptidase inhibitor activity GO:0004867 8.8 SPINK5 SERPINB3 PEBP1

Sources for Anus Benign Neoplasm

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
71 Tocris
73 UMLS via Orphanet
Loading form....